Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug

Lemtrada Stroke Lawsuit News

Patients may now choose Kesimpta before their disease progresses to the stage that requires Lemtrada

Tuesday, August 25, 2020 - Experts that recommend disease-modifying therapies (DMT)s are unanimous in their opinion that patients should have a multitude of choices depending on the extent and progression of their disease. Relapse remitting multiple sclerosis (RRMS) is progressive and permanent, and patients are told that it is a disease that they will not die from, but is a disease that they will die with. Bruce Bebo, Ph.D., executive vice president of research at the National MS Society described his philosophy on the DMTs to Multiple Sclerosis News Today, "Multiple sclerosis (MS) is a complex disease, and response to disease-modifying treatment will vary among individuals. This makes it important to have a range of treatments available with different mechanisms of action and routes of administration." Lemtrada attorneys are helping people suffering from Lemtrada side effects and offer a free consultation with no obligation to file.

Most recently, the U.S. Food and Drug Administration (FDA) approved a new drug for the treatment of secondary progressive multiple sclerosis (SPMS) called Kesimpta (ofatumumab). Doctors specializing in treating RRMS were thrilled with being able to offer the drug to patients and called it wonderful news for patients with RRMS. Kesimpta is self-injected using an autoinjector pen in the comfort and convenience of their home once per month. Kesimpta works by "lowering the number of B-cells that drive damaging inflammation in the nervous system and contribute to multiple sclerosis development. According to Novartis, Kesimpta is the first approved multiple sclerosis therapy targeting B-cells that can be taken at home via an under-the-skin (subcutaneous) injection, using an autoinjector pen, once a month. The medication may be available to patients in early September," Multiple Sclerosis News wrote. RRMS patients prefer auto-injection over hospital visits because it is less costly and more convenient and gives the patient easier access to the treatment. Kisempta carries surprisingly few known side effects other than upper respiratory tract infection, headache, injection-related reactions, and local injection site reactions, according to Novartis.

While RRMS patients hope to maximize the number of months or years that they can remain on the Kesimpta treatment, they know that RRMS is a progressive disease that needs ever-more-toxic therapy. Patients may grow increasingly desperate and willing to try just about anything. The DMT drug of choice when all hope is lost to treat advanced stages of RRMS is Lemtrada. Lemtrada is a drug of last resort and only recommended when two or more other DMTs have ceased working. Lemtrada doctors and potential patients must first fill out a questionnaire explaining life-threatening risks the drug caries like causing instant death from having a stroke or heart attack. Fatal side effects of Lemtrada may occur within 72 hours of the Lemtrada treatment. Lemtrada must be administered at a hospital with an emergency room available. If you or a loved one have suffered a Lemtrada stroke or heart attack and were unaware of the drug's potentially fatal side effects, you may wish to file a claim.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.